11.05
11.05 (0%)
As of May 09, 2024
Priveterra Acquisition Corp. [PMGM]
Source:
Company Overview
Aeon Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing our botulinum toxin complex, prabotulinumtoxinA injection (“ABP-450”), for debilitating medical conditions, with an initial focus on the neurosciences market.
| Country | United States |
| Headquarters | fort lauderdale, florida |
| Phone Number | (407) 808-1335 |
| Industry | |
| CEO | Marc Forth |
| Website | clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-318.4 |
| Net Income | $-324 |
| Net Cash | $-26.1 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -6,487.5% |
| Profit as % of Stockholder Equity | 1,133.9% |
Management Effectiveness
| Return on Equity | 1,133.9% |
| Return on Assets | -10,310.4% |
| Turnover Ratio | |
| EBITA | $-318.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $3.1 |
| Total Liabilities | $31.7 |
| Operating Cash Flow | $-26.1 |
| Investing Cash Flow | |
| Financing Cash Flow | $0 |
